Brief: Pliant Therapeutics Announces Positive Data From The INTEGRIS-IPF Phase 2a Trial

Pliant Therapeutics

22/01/2023 19:04

Jan 22 (Reuters) - Pliant Therapeutics Inc  PLRX.O :
    * PLIANT THERAPEUTICS ANNOUNCES POSITIVE DATA FROM THE
INTEGRIS-IPF PHASE 2A TRIAL DEMONSTRATING BEXOTEGRAST 320 MG WAS
WELL TOLERATED AND ACHIEVED STATISTICALLY SIGNIFICANT FVC
INCREASE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    * BEXOTEGRAST DEMONSTRATED STATISTICALLY SIGNIFICANT
INCREASE IN
FVC AT 4,8,12 WEEKS OF TREATMENT, OUTPERFORMING LOWER DOSE
GROUPS
    * NO BEXOTEGRAST-TREATED PATIENTS EXPERIENCED DISEASE
PROGRESSION
AS DEFINED BY FVCPP DECLINE OF GREATER THAN OR EQUAL TO 10%
    * BEXOTEGRAST WAS WELL TOLERATED OVER 12 WEEKS OF TREATMENT
WITH
NO DRUG-RELATED SEVERE OR SERIOUS ADVERSE EVENTS
    * DATA FROM 320 MG GROUP OF INTEGRIS-IPF TRIAL IN PATIENTS
TREATED
FOR AT LEAST 24 WEEKS ARE EXPECTED IN Q2 OF 2023
    * IS PLANNING TO INITIATE A PHASE 2B CLINICAL TRIAL OF
BEXOTEGRAST
IN MID-2023

Source text for Eikon:  ID:nGNX6GwbK8 
Further company coverage:  PLRX.O 
 ((Reuters.Briefs@thomsonreuters.com;))